Trial · NCT03842709

Non-Opioid Pramipexole and Pain

NCT03842709, Early phase 1, Completed, University of New Mexico; results first posted 2024-10-23

3 sourcestrials-2026-11-12-0.4.0

Cite this record

ConductScience Library. Non-Opioid Pramipexole and Pain. Trials, record NCT03842709. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03842709

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Non-Opioid Pramipexole and Pain
NCT number: NCT03842709
Status: Completed
Phases: Early phase 1
Enrollment: 13 participants, actual
Lead sponsor: University of New Mexico
Conditions: Chronic Pain
Interventions: Pramipexole Oral Tablet, Placebo
First posted: 2019-02-15
Last updated: 2024-10-23
Results first posted: 2024-10-23

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Brief Pain Inventory Score	4 weeks	Change in self-reported effect of pain on quality of life. The "Brief Pain Inventory, Short Form," instrument will be used. It records severity (0-10 scale; 10= worst pain) at its worst.
Secondary	mRNA Results IL-1b	4 weeks	Fold change of the mRNA gene expression from the house keeping gene and the controls.

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Brief Pain Inventory Score	4 weeks		score on a scale	MEAN
SECONDARY	mRNA Results IL-1b	4 weeks	Four participants did not provide relevant blood samples.	Fold change	MEAN

Source ClinicalTrials.gov

Results by group4

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Brief Pain Inventory Score	Standard Treatment + Placebo	8	Standard Deviation 1	score on a scale
Brief Pain Inventory Score	Standard Treatment + Pramipexole	6.7	Standard Deviation 3.2	score on a scale
mRNA Results IL-1b	Standard Treatment + Placebo	16.1	Standard Deviation 8.1	Fold change
mRNA Results IL-1b	Standard Treatment + Pramipexole	8.6	Standard Deviation 8.6	Fold change

Source ClinicalTrials.gov

Participant flow8

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Standard Treatment + Placebo	7
Overall Study	STARTED	Standard Treatment + Pramipexole	6
Overall Study	Initiated Treatment	Standard Treatment + Placebo	6
Overall Study	Initiated Treatment	Standard Treatment + Pramipexole	5
Overall Study	COMPLETED	Standard Treatment + Placebo	3
Overall Study	COMPLETED	Standard Treatment + Pramipexole	3
Overall Study	NOT COMPLETED	Standard Treatment + Placebo	4
Overall Study	NOT COMPLETED	Standard Treatment + Pramipexole	3

Source ClinicalTrials.gov

Adverse events2

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	dizziness	Nervous system disorders	Standard Treatment + Placebo	0	6	0
other	dizziness	Nervous system disorders	Standard Treatment + Pramipexole	1	5	1

Source ClinicalTrials.gov

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Standard Treatment + Placebo	0	6
Total, all-cause mortality	Standard Treatment + Pramipexole	0	5
Total, other adverse events	Standard Treatment + Placebo	0	6
Total, other adverse events	Standard Treatment + Pramipexole	1	5
Total, serious adverse events	Standard Treatment + Placebo	0	6
Total, serious adverse events	Standard Treatment + Pramipexole	0	5

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Standard Treatment + Placebo vs Standard Treatment + Pramipexole: deaths from any cause	Trial comparisons
Standard Treatment + Placebo vs Standard Treatment + Pramipexole: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Source

Release: trials-2026-11-12-0.4.0
Release manifest SHA-256: 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
Registry capture: 2026-11-12
Results copy, AACT: 2026-03-23
NIH clinical studies file: 2026-11-13

Source ClinicalTrials.gov

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNone stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03842709

GET https://conductscience.org/api/trials/v1/NCT03842709/registered

API reference For AI assistants